

# Kento Umino

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/856908/publications.pdf>

Version: 2024-02-01

43  
papers

271  
citations

1040056

9  
h-index

1125743

13  
g-index

43  
all docs

43  
docs citations

43  
times ranked

457  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk Factors for Complications Associated with Peripherally Inserted Central Catheters During Induction Chemotherapy for Acute Myeloid Leukemia. <i>Internal Medicine</i> , 2022, 61, 989-995.	0.7	3
2	Relationship of tumor load parameters before and after autologous stem cell transplantation with clinical prognosis in transplant-eligible patients with multiple myeloma: A retrospective analysis. <i>Leukemia Research</i> , 2022, 112, 106750.	0.8	1
3	Urine Xanthine Crystals in Hematologic Malignancies with Tumor Lysis Syndrome. <i>Internal Medicine</i> , 2022, 61, 3271-3275.	0.7	3
4	Dimethyl fumarate ameliorates graft-versus-host disease by inhibiting T cell metabolism and immune responses through a reactive oxygen species-dependent mechanism. <i>British Journal of Haematology</i> , 2022, , .	2.5	0
5	Impact of muscle mass loss assessed by computed tomography on the outcome of allogeneic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2022, 63, 1694-1700.	1.3	2
6	Clinical interaction between dexamethasone and aprepitant in chemotherapy for lymphoma. <i>Annals of Hematology</i> , 2022, 101, 1211-1216.	1.8	2
7	Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma. <i>Blood</i> , 2022, 140, 594-607.	1.4	14
8	Identification of endoscopic factors that predict poor responses to steroids in patients with gastrointestinal acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 963-967.	2.4	1
9	Clinical association between thyroid disease and immune thrombocytopenia. <i>Annals of Hematology</i> , 2021, 100, 345-352.	1.8	11
10	Mesenchymal Stromal Cells Inhibit Aerobic Glycolysis in Activated T Cells by Negatively Regulating Hexokinase II Activity Through PD-1/PD-L1 Interaction. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 231.e1-231.e8.	1.2	3
11	Risk factors for high-dose methotrexate-induced nephrotoxicity. <i>International Journal of Hematology</i> , 2021, 114, 79-84.	1.6	12
12	The impact of overweight on renal toxicity in patients treated with dexamethasone, high-dose cytarabine, and cisplatin. <i>International Journal of Hematology</i> , 2020, 111, 396-400.	1.6	1
13	Comparison of Danaparoid Sodium and Synthetic Protease Inhibitors for the Treatment of Disseminated Intravascular Coagulation Associated with Hematological Malignancies: A Retrospective Analysis. <i>Acta Haematologica</i> , 2020, 143, 250-259.	1.4	5
14	Evaluation of thrombotic events in patients with immune thrombocytopenia. <i>Annals of Hematology</i> , 2020, 99, 49-55.	1.8	9
15	Salvage Chemotherapy Followed by Autologous Stem-Cell Transplantation Using Targeted Busulfan for Refractory Diffuse Large B-Cell Lymphoma With Dialysis-Dependent End-Stage Renal Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e92-e96.	0.4	3
16	Steep neutrophil recovery following unrelated bone marrow transplantation is a major risk factor for the development of acute graft-versus-host disease—a retrospective study. <i>Transplant International</i> , 2020, 33, 1723-1731.	1.6	5
17	Impact of prednisolone dosage in the CHOP regimen for follicular lymphoma: a retrospective study. <i>International Journal of Hematology</i> , 2020, 112, 369-376.	1.6	1
18	Factors that predict delayed platelet recovery after autologous stem cell transplantation for lymphoma or myeloma. <i>Annals of Hematology</i> , 2020, 99, 2893-2901.	1.8	4

#	ARTICLE	IF	CITATIONS
19	Differential Localization and Invasion of Tumor Cells in Mouse Models of Human and Murine Leukemias. <i>Acta Histochemica Et Cytochemica</i> , 2020, 53, 43-53.	1.6	1
20	Dimethyl Fumarate Ameliorates Graft-Versus-Host Disease By Negatively Regulating Aerobic Glycolysis in Alloreactive T-Cells. <i>Blood</i> , 2020, 136, 24-25.	1.4	1
21	Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies. <i>International Journal of Hematology</i> , 2019, 109, 141-146.	1.6	26
22	Predictive value of soluble interleukin-2 receptor level at diagnosis on the outcome for patients with classical Hodgkin lymphoma treated with ABVD with or without radiotherapy. <i>Annals of Hematology</i> , 2019, 98, 2121-2129.	1.8	3
23	TAFRO Syndrome with an Anterior Mediastinal Mass and Lethal Autoantibody-Mediated Thrombocytopenia: An Autopsy Case Report. <i>Acta Haematologica</i> , 2019, 141, 158-163.	1.4	4
24	Impact of the soluble interleukin-2 receptor level in the relapsed or refractory phase on the clinical outcome of patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1926-1933.	1.3	3
25	Prognostic impact of serum soluble interleukin-2 receptor level at diagnosis in elderly patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Leukemia and Lymphoma</i> , 2019, 60, 734-741.	1.3	9
26	Associations between the peripheral blood Wilms tumor gene 1 level and both bone marrow blast cells and the prognosis in patients with myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 2019, 60, 703-710.	1.3	7
27	Comparison of blast percentage calculated based on bone marrow all nucleated cells and non-erythroid cells in myelodysplastic syndromes with erythroid hyperplasia. <i>Annals of Hematology</i> , 2019, 98, 1127-1133.	1.8	0
28	Steep Neutrophil Recovery Following Unrelated Bone Marrow Transplantation Is a Major Risk Factor for the Development of Acute Graft-Vs-Host Disease. <i>Blood</i> , 2019, 134, 5686-5686.	1.4	0
29	Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 ( <i>FGFR1</i> ) rearrangement. <i>Hematology</i> , 2018, 23, 470-477.	1.5	28
30	A leukemic double-hit follicular lymphoma associated with a complex variant translocation, <i>t(8;14;18)(q24;q32;q21)</i> , involving <i>BCL2</i> , <i>MYC</i> , and <i>IGH</i> . <i>Cancer Genetics</i> , 2018, 220, 44-48.	0.4	3
31	Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia. <i>International Journal of Hematology</i> , 2018, 107, 712-715.	1.6	7
32	False-positive elevation of 1,3-beta-D-glucan caused by continuous administration of penicillin G. <i>Journal of Infection and Chemotherapy</i> , 2018, 24, 812-814.	1.7	14
33	Role of Sequential Monitoring of <i>WT1</i> Gene Expression in Patients With Acute Myeloid Leukemia for the Early Detection of Leukemia Relapse. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e521-e527.	0.4	14
34	Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 316-323.	1.3	10
35	The prognostic significance of rapid peripheral blood blast clearance during the initial course of induction chemotherapy in young patients with de novo acute myeloid leukemia. <i>Hematological Oncology</i> , 2017, 35, 357-364.	1.7	0
36	Development of acute myeloid leukemia in patients with untreated chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2017, 96, 719-724.	1.8	9

#	ARTICLE	IF	CITATIONS
37	High-Dose Methotrexate and Cytarabine-Based Multi-Agent Chemotherapy (Modified Bonn Protocol) for Systemic Lymphoma with CNS Involvement. <i>Acta Haematologica</i> , 2017, 137, 93-99.	1.4	4
38	Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP. <i>Hematology</i> , 2017, 22, 521-526.	1.5	10
39	Relationship between white blood cell count elevation and clinical response after G-CSF priming chemotherapy for acute myeloid leukemia. <i>International Journal of Hematology</i> , 2017, 106, 411-417.	1.6	2
40	Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 2541-2547.	1.3	4
41	A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis. <i>Leukemia Research</i> , 2016, 42, 82-87.	0.8	12
42	Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan. <i>Annals of Hematology</i> , 2016, 95, 1513-1519.	1.8	20
43	Comprehensive Analysis of Activation and Proliferation Kinetics and Effector Functions of Human Lymphocyte Subsets in Xenogeneic GvHD Model. <i>Blood</i> , 2016, 128, 3350-3350.	1.4	0